Asset profile
CD123 targeted CAR-NK cells
Cell therapy
Evidence outlook · results not reported
NCT06006403 · Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse...
The lead study uses a design that frequently fails to replicate under controlled conditions, and its results have not been reported. This tier describes the design, not an outcome.
NCT06006403: This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| CD123 Targeted CAR-NK Cells: this drug | Phase 1/2 | Cell therapy | CD123 | ||
| Pivekimab Sunirine | Phase 2/3 | Antibody–drug conjugate | CD123 | ||
| Tagraxofusp | Phase 2 | — | CD123 | ||
| SAR443579 | Phase 1/2 | Biologic (subtype unspecified) | CD123 | ||
| Allo-RevCAR01-T | Phase 1 | — | CD123 | ||
| Anti-CD123 CAR NK Cells | Phase 1 | — | CD123 | ||
| BYON4413 | Phase 1 | — | CD123 | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Midostaurin | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | ||
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | ||
| Quizartinib | Approved | Small molecule | FLT3 | ||
| Revumenib | Approved | Small molecule | Menin | ||
| Tretinoin (Vesanoid) | Approved | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.